Remove tag national-institute-health-research
article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

Fleurence, PhD, MSc Senior Advisor National Institutes of Health Joshua M. To address this crisis, the NIH is embarking on a National Initiative on Hepatitis C.       Speakers Rachael L. with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020. Rates are the highest among 20-39-year-olds.

article thumbnail

Grand Rounds August 19, 2022: Inclusion and Diversity in Clinical Trials: Actionable Steps to Drive Lasting Change (Gerald Bloomfield, MD, MPH; Michelle Kelsey, MD)

Rethinking Clinical Trials

Associate Professor, Global Health. There is a national priority to increase diversity in clinical trials, from regulatory, funding agencies, industry, and others, so that the participant population reflects the U.S. This is an issue that a number of institutions have been thinking about for some time. Michelle Kelsey, MD.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 6, 2023: Hybrid Studies Should Not Sacrifice Rigorous Methods (David M. Murray, PhD; Moderator: Jonathan Moyer, PhD)

Rethinking Clinical Trials

The use of the term “hybrid design” is unfortunate, as it suggests that implementation research has different methods than other research and might not be held to the same standards. Instead, we should use the same rigorous methods for implementation research that we use for other research and simply change the focus.

article thumbnail

Grand Rounds July 8, 2022: Results From the COVID-OUT Trial, A Phase-3 Trial of Outpatient Treatment for Covid-19 Using Metformin, Ivermectin, and Fluvoxamine (Carolyn Bramante, MD, MPH; Thomas Murray, PhD; Jared Huling, PhD)

Rethinking Clinical Trials

Core Faculty, Program for Health Disparities Research. University of Minnesota School of Public Health. University of Minnesota School of Public Health. Some aspects were a success, particularly delivery of study medication nation-wide within 1 day of consent. University of Minnesota Medical School. Key Points.

Trials 130
article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

“Access to medicines remains one of the most challenging policy areas in every country we work with through the pan-European region,” said Natasha Muscat, Director of Country Health Policies and Systems at World Health Organization (WHO) Europe. WHO is OMI?

article thumbnail

Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA

XTalks

With a price tag of over $2.5 In England, five-month old baby Arthur became the country’s first SMA patient to receive the Zolgensma gene therapy last week through the National Health Service (NHS). The researchers conducted a long-term follow-up study of the START trial that included patients who completed phase I of the study.

article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” billion in 2027. .

Drugs 98